PURPOSE: We evaluated the efficiency and toxicity of stereotactic hypofractionated boost in combination with conventionally fractionated radiotherapy in the treatment of advanced floor of the mouth cancer. METHODS: Thirty-seven patients with advanced stage of the floor of the mouth cancer, histologically confirmed squamous cell carcinoma (p16 negative) ineligible for surgical treatment, were indicated for radiochemotherapy or hyperfractionated accelerated radiotherapy (HART). The radiotherapy protocol combined external beam radiotherapy (EBRT) and a stereotactic hypofractionated boost to the primary tumor. The dose delivered from EBRT was 70-72.5 Gy in 35/50 fractions. The hypofractionated boost followed with 10 Gy in two fractions. For the variables-tumor volume, stage and grade a multivariate analysis was performed to find the relationship between overall survival, local progression and metastasis. Toxicity was evaluated according to CTCAE scale version 4. RESULTS: After a median follow-up of 16 months, 23 patients (62%) achieved complete remission. The median time to local progression and metastasis was 7 months. Local control (LC) at 2 and 5-years was 70% and 62%, respectively. Progression-free survival (PFS) and overall survival (OS) were 57% and 49% at 2 years and 41% and 27% at 5 years, respectively. Statistical analysis revealed that larger tumors had worse overall survival and a greater chance of metastasis. Log-Rank GTV > 44 ccm (HR = 1.96; [95% CI (0.87; 4.38)]; p = 0.11). No boost-related severe acute toxicity was observed. Late osteonecrosis was observed in 3 patients (8%). CONCLUSION: The combination of EBRT and stereotactic hypofractionated boost is safe and seems to be an effective option for dose escalation in patients with advanced floor of the mouth tumors who are ineligible for surgical treatment and require a non-invasive approach.

Department of Oncology University Hospital Královské Vinohrady Prague Prague Czech Republic

Department of Oncology University Hospital Ostrava Ostrava Czech Republic

Department of Oral and Maxillofacial Surgery University Hospital Ostrava Ostrava Czech Republic

Department of Otorhinolaryngology University Hospital Ostrava Ostrava Czech Republic

Department of Pathology University Hospital Ostrava Ostrava Czech Republic

Faculty of Medicine Palacký University Olomouc Olomouc Czech Republic

Faculty of Medicine University of Ostrava Ostrava Czech Republic

Institute of Animal Physiology and Genetics Czech Academy of Sciences Brno Czech Republic

Rd Faculty of Medicine Charles University Prague Prague Czech Republic

Zobrazit více v PubMed

Chen AY, Myers JN. Cancer of the oral cavity. Dis Mon. 2001;47(7):275–361. doi: 10.1067/mcd.2001.109374. PubMed DOI

Saggi S, Badran KW, Han AY, Kuan EC, John MA. Clinicopathologic characteristic and survival outcomes in the floor of mouth squamous cell carcinoma: A population-based study. Otolaryngol Head Neck Surg 2018;159(1):51–58. PubMed

Ellis MA, Graboyes EM, Wahlquist AE, Neskey DM, Kaczmar JM, Schopper HK. Primary surgery vs radiotherapy for early oral cavity cancer. Otolaryngol Head Neck Surg. 2018;158(4):649–659. doi: 10.1177/0194599817746909. PubMed DOI

Fujiwara R, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki C. Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: primary surgical resection vs nonsurgical treatment. Oral Oncol 2017;71:129–137. PubMed

Ellis MA, Graboyes EM, Wahlquist AE, Neskey DM, Kaczmar JM, Schopper HK, et al. Primary surgery vs radiotherapy for early stage oral cavity cancer. Otolaryngol Head Neck Surg. 2018;158:649–659. doi: 10.1177/0194599817746909. PubMed DOI

Ow TJ, Myers JN. Current management of advanced resectable oral cavity squamous cell carcinoma. Clin Exp Otorhinolaryngol. 2011;4(1):1–10. doi: 10.3342/ceo.2011.4.1.1. PubMed DOI PMC

Hosni A, Chiu K, Huang SH, Xu W, Huang J, Bayley A. Non-operative management for oral cavity carcinoma: definitive radiation therapy as a potential alternative treatment approach. Radiother Oncol. 2020;154:70–75. doi: 10.1016/j.radonc.2020.08.013. PubMed DOI PMC

Yao M, et al. Intensity-modulated radiation therapy for head-and-neck squamous cell carcinoma-the University of Iowa experience. Int J Radiat Oncol Biol Phys. 2005;63(2):410–421. doi: 10.1016/j.ijrobp.2005.02.025. PubMed DOI

Robertson AG, et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumors. Clin Oncol. 1998;10(3):155–160. doi: 10.1016/S0936-6555(98)80055-1. PubMed DOI

Studer G, Luetolf UM, Glanzmann C. Locoregional failure analysis in head-and-neck cancer patients treated with IMRT. Strahlenther Onkol. 2007;183:417–423. doi: 10.1007/s00066-007-1663-8. PubMed DOI

Atwell D, Elks J, Cahill K, Hearn D. A review of modern radiation therapy dose escalation in locally advanced head and neck cancer. Clin Oncol. 2020;32(5):330–341. doi: 10.1016/j.clon.2019.12.004. PubMed DOI

Studer G, et. al. Osteoradionecrosis of the mandible. minimized risk profile following intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 2006;182(5):283–288. PubMed

Lozza L, et al. Analysis of risk factors for mandibular bone radionecrosis after exclusive low dose-rate brachytherapy for oral cancer. Radiother Oncol. 1997;44(2):143–147. doi: 10.1016/S0167-8140(97)00092-3. PubMed DOI

Kovács G, Martinez-Monge R, Budrukkar A, Guinot J, Johansson B, Strnad V. GEC-ESTRO ACROP recommendations for head and neck brachytherapy in squamous cell carcinomas: 1st update—improvement by cross-sectional imaging-based treatment planning and stepping source technology. Radiother Oncol. 2017;122(2):248–254. doi: 10.1016/j.radonc.2016.10.008. PubMed DOI

Julianna R, Voichita Bar-Ad, Cognetti D, Curry J, et al. A systemic review of treating head and neck cancer: a reintroduction of brachytherapy with or without surgery. J Contemp Brachytherapy 2018;10,5:454–462. PubMed PMC

Zeno AR, Gouw MD, Matthew D, et al. Single-center prospective trial investigating the feasibility of seriál FDG-PET guided adaptive radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2020;108(4):960–968. doi: 10.1016/j.ijrobp.2020.04.030. PubMed DOI

Vempati P, Halthore A, Teckie S, et al. Phase I trial of dose-escalated stereotactic radiosurgery (SRS) boost for unfavourable locally advanced oropharyngeal cancer. Radiat Oncol. 2020;15:278–288. doi: 10.1186/s13014-020-01718-w. PubMed DOI PMC

Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol. 2007;30(6):637–644. doi: 10.1097/COC.0b013e3180ca7cb1. PubMed DOI

Cvek J, Kubes J, Skacelikova E, Otahal B, Kominek P, Halamka M, Feltl D. Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70–75Gy in 5 weeks for advanced head and neck cancer. Strahlenter Onkol. 2012;188(8):666–670. doi: 10.1007/s00066-012-0128-x. PubMed DOI

Al-Mamgani A, Van Rooij P, Sewnaik A, Mehilal R, et al. Brachytherapy or stereotactic body radiotherapy boost for early-stage oropharyngeal cancer: comparable outcomes of two different approaches. Oral Oncol. 2013;49:1018–1024. doi: 10.1016/j.oraloncology.2013.07.007. PubMed DOI

Strnad V. Treatment of oral cavity and oropharyngeal cancer. Indications, technical aspects, and results of interstitial brachytherapy. Strahlenther Onkol 2004;180(11):710–717. PubMed

Dearnaley DP, et al. Interstitial irradiation for carcinoma of the tongue and floor of the mouth: Royal Marsden Hospital Experience 1970–1986. Radioher Oncol. 1991;21(3):183–192. doi: 10.1016/0167-8140(91)90036-G. PubMed DOI

Mohanti BK, Bansal M, Bahadur S, Shukla NK, Deo SV, Prabhakar R, Rath GK. Interstitial brachytherapy with or without external beam irradiation in head and neck cancer: Institute Rotary Cancer Hospital experience. Clin Oncol (R Coll Radiol) 2001;13(5):345–352. PubMed

Sanguienti G, Rao N, Gunn B, et al. Predictors of PEG dependence after IMRT± chemotherapy for oropharyngeal cancer. Radiother Oncol. 2013;107:300–304. doi: 10.1016/j.radonc.2013.05.021. PubMed DOI

Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol. 2010;28:2732–2738. doi: 10.1200/JCO.2009.24.6199. PubMed DOI PMC

Foster CC, Melotek JM, Brisson RJ, Seiwert TY, Cohen EE, Stenson KM, et al. Definitive chemoradiation for locally-advanced oral cavity cancer: a 20-year experience. Oral Oncol. 2018;80:16–22. doi: 10.1016/j.oraloncology.2018.03.008. PubMed DOI

Yamazaki H, Ogita M, Himei K, et al. Hypofractionated stereotactic radiotherapy using CyberKnife as a boost treatment for head and neck, a multi-institutional survey: impact of planning target volume. Anticancer Res. 2014;34:5755–5760. PubMed

Decroix Y, Ghossein NA. Experience of the Curie Institute in treatment of cancer of the mobile tongue: I. Treatment policies and result. Cancer 1981;47(3):496–502. PubMed

Pernot M, et al. Evaluation of the importance of systematic neck dissection in carcinoma of the oral cavity treated by brachytherapy alone for the primary lesion (apropos of a series of 346 patients) Bull Cancer Radiother. 1995;82(3):311–317. doi: 10.1016/0924-4212(96)81500-3. PubMed DOI

Scher EF, Romesser PB, Chen C, Ho F, Wuu Y, Sherman EJ, et al. Definitive chemoradiation for primary oral cavity carcinoma: a single institution experience. Oral Oncol. 2015;51:709–715. doi: 10.1016/j.oraloncology.2015.04.007. PubMed DOI PMC

Eder T, Hess AK, Konschak C, Stromberger K, Jöhrens K, Fleischer V, et al. Interference of tumour mutational burden with the outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. Eur J Cancer. 2019;116:67–76. doi: 10.1016/j.ejca.2019.04.015. PubMed DOI

High PD-L1 expression on immune cells along with increased density of tumor-infiltrating lymphocytes predicts a favorable survival outcome for patients with loco-regionally advanced head and neck cancer: early results from a prospective study

HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy